Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31631922 | 0.83 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL14151718 | 0.82 | GRM5 (0.35) | DGAT1 | |
| SCHEMBL22093251 | 0.80 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL5764924 | 0.79 | KDM4E (0.35) | DGAT1 | |
| SCHEMBL22093263 | 0.79 | CPB1 (0.33) | DGAT1 | |
| SCHEMBL3841245 | 0.77 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL2473549 | 0.76 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL13560614 | 0.75 | SMYD2 (0.35) | DGAT1 | |
| SCHEMBL15613781 | 0.74 | GRM5 (0.32) | DGAT1 | |
| SCHEMBL18431180 | 0.74 | DGAT1 (0.32) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2020210828-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-1828171-B1 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2014-03-12 | — | — | EP | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| US-7081466-B2 | 2-aroylimidazole compounds for treating cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20040186129-A1 | 2-Aroylimidazole compounds for treating cancer | KOYA KEIZO (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1427413-A2 | 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER | Synta Pharmaceuticals Corporation (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6743919-B2 | INCLUDING MULTI-DRUG RESISTANT CANCER CELLS FROM A NUMBER OF DIFFERENT TISSUE TYPES | SYNTA PHARMACEUTICALS CORP. | 2004-06-01 | — | — | US | disclosed |
| US-20030096836-A1 | 2-Aroylimidazole compounds for treating cancer | SBR PHARMACEUTICALS CORP. | 2003-05-22 | — | — | US | disclosed |
| WO-2003022274-A2 | 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC5, HDAC11 | DUT 1822/4885DGAT1 2075/4885 |
| US-20030096836-A1 | 2-Aroylimidazole compounds for treating cancer | NR4A1, NR0B2, NR0B1 | DUT 155/4885DGAT1 3518/4885 |
| US-20040186129-A1 | 2-Aroylimidazole compounds for treating cancer | TOP2B, HDAC11, CYP4B1 | DUT 106/4885DGAT1 3457/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | DUT 1315/4885DGAT1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.